Silexion Therapeutics Corp
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
SLXN$0.11-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| 2025 | 2024 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(11,912) | $(16,519) |
| Adjustments required to reconcile loss to net cash used in operating activities: | ||
| Depreciation | 14 | 25 |
| Share-based compensation expenses | 134 | 5,862 |
| Non-cash loss upon entering Transactions | - | 4,783 |
| Other non-cash financial expenses (income) | 344 | (1,051) |
| Loss (gain) on disposal of property and equipment | - | 16 |
| Loss from lease termination | - | 68 |
| Changes in operating assets and liabilities: | ||
| Decrease (increase) in prepaid expenses | 396 | (631) |
| Decrease (increase) in other current assets | 13 | (38) |
| Increase (decrease) in trade payable | (142) | 610 |
| Net change in operating lease | (5) | (57) |
| Increase in employee related obligations | 237 | 435 |
| Increase (decrease) in other accounts payable | 102 | (1,899) |
| Net cash used in operating activities | (10,819) | (8,396) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Investment in long-term deposits | (5) | - |
| Purchase of property and equipment | (9) | (22) |
| Net cash used in investing activities | (14) | (22) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of ordinary shares upon January 2025 and September 2025 public offerings | 11,000 | - |
| Issuance costs related to public offerings | (1,530) | - |
| Proceeds from exercise of warrants | 2,644 | - |
| Proceeds from issuance of ordinary shares upon January 2025 and August 2025 warrants inducement transactions | 5,036 | - |
| Issuance costs related to warrants inducement transactions | (740) | - |
| Payment of Underwriters Promissory Note | (696) | (250) |
| Prepaid of issuance cost related to At the Market Offering | (74) | - |
| Proceeds from exercise of pre-funded options | * | * |
| Net proceeds from issuance of ordinary shares (ELOC) | - | 3,054 |
| Cash received from Transactions upon the effectiveness of the SPAC Merger | - | 2,300 |
| Net cash provided by financing activities | 15,640 | 5,104 |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | 4,807 | (3,314) |
| EXCHANGE RATE DIFFERENCES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (2) | (61) |
| BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR | 1,270 | 4,645 |
| BALANCE OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR | $6,075 | $1,270 |
F - 7
CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2025 | 2024 | |
|---|---|---|
| Appendix A – | ||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH REPORTED IN THE CONSOLIDATED BALANCE SHEETS: | ||
| Cash and cash equivalents | 5,991 | 1,187 |
| Restricted cash | 84 | 83 |
| TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS | $6,075 | $1,270 |
| Appendix B - SUPPLEMENTARY INFORMATION: | ||
| SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: | ||
| Derecognition of right-of-use asset recognized and lease liability as a result of operating lease termination | - | $(89) |
| Conversion of preferred shares to ordinary shares | - | $15,391 |
| Conversion of warrants to preferred shares on a cashless basis | - | $334 |
| Conversion of non-controlling interests to Silexion ordinary shares | - | $3,344 |
| Conversion of Underwriters Promissory Note to ordinary shares | $356 | - |
| Conversion of Related Party Promissory Note to ordinary shares | $1,624 | - |
| Accrued and unpaid issuance expenses in respect of public offering | $20 | - |
| Shares issued for ELOC financing liability | - | $312 |
| Right-of-use asset recognized with a corresponding lease liability | - | $506 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | ||
| Interest paid | $13 | $27 |
| Interest received | $155 | $28 |
F - 8
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.